December 4, 2017
VIA EDGAR AND HAND DELIVERY
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
|
Attention: |
|
Tim Buchmiller |
|
|
|
Geoff Kruczek |
|
|
|
Gary Newberry |
|
|
|
Kevin Kuhar |
|
|
|
Amanda Ravitz |
|
Re: |
|
Quanterix Corporation (the “Company”) |
|
|
|
Registration Statement on Form S-1 |
|
|
|
File No. 333-221475 |
Ladies and Gentleman:
In connection with the above-referenced Registration Statement, we wish to advise you that between November 27, 2017 and the date hereof we effected the distribution of approximately 2,650 copies of the Company’s Preliminary Prospectus dated November 27, 2017 to prospective underwriters, institutional investors, prospective dealers, brokers, individuals, rating agencies and others.
We will comply and have been informed by the other participating underwriters that they will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
As Representatives of the several underwriters, we hereby join in the request of the Company that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:05 p.m., Washington, D.C. time, on December 6, 2017, or as soon thereafter as practicable.
[Signatures follow.]
|
|
Very truly yours, | |||
|
|
| |||
|
|
| |||
|
|
J.P. MORGAN SECURITIES LLC, | |||
|
|
LEERINK PARTNERS LLC | |||
|
|
COWEN AND COMPANY LLC | |||
|
|
As Representatives of the several Underwriters | |||
|
|
| |||
|
|
J.P. MORGAN SECURITIES LLC | |||
|
|
| |||
|
|
| |||
|
|
By: |
/s/ David Ke | ||
|
|
Name: |
David Ke | ||
|
|
Title: |
Vice President | ||
|
|
|
| ||
|
|
|
| ||
|
|
LEERINK PARTNERS LLC | |||
|
|
|
| ||
|
|
|
| ||
|
|
By: |
/s/ John I. Fitzgerald, Esq. | ||
|
|
Name: |
John I. Fitzgerald, Esq. | ||
|
|
Title: |
Managing Director | ||
|
|
|
| ||
|
|
|
| ||
|
|
COWEN AND COMPANY LLC | |||
|
|
|
| ||
|
|
|
| ||
|
|
By: |
/s/ Michael Campbell | ||
|
|
Name: |
Michael Campbell | ||
|
|
Title: |
Managing Director | ||
[Signature Page to Request for Acceleration of Effectiveness]